Introduction
Although the World Health Organization (WHO) launched the ambitious End TB Strategy in 2015, 1 tuberculosis (TB) remains the leading infectious cause of death worldwide. The WHO estimates that 10.4 million people developed TB in 2014, of whom 580 000 had multidrug-resistant (MDR) or rifampicin-monoresistant TB. 2 The huge disease burden suffered by children in TB endemic countries was rarely appreciated in the past, 3 but this has changed with high-level advocacy and better data to improve visibility. [4] [5] [6] Recently the United Nations Secretary-General's Special Envoy on TB Dr Eric Goosby stated: ''For far too long, children with tuberculosis (TB) have remained in the shadows. While there have been tremendous strides made in improving other areas of child health and survival, we have yet to see the parallel advances in pediatric TB. Instead, many children with TB die before they can be diagnosed and treated''. 4 The WHO estimates that one million children developed TB in 2015, resulting in 210 000 deaths. 2, 7 At least 5000 children were likely to have died from multidrugresistant TB and around 40 000 were co-infected with HIV. 7, 8 In the absence of routine drug susceptibility testing (DST), MDR-TB estimates are highly variable and the number of affected children often underappreciated. 7, 8 This mainly results from the fact that the level of primary MDR-TB transmission within endemic communities is grossly underestimated when extrapolated from the MDR-TB rate observed among new TB cases only. In reality, the majority of MDR-TB diagnosed among retreatment cases also represents primary transmission. [9] [10] [11] Children dying from TB, including drug-resistant disease, are often incorrectly classified as pneumonia, meningitis, HIV/AIDS, or malnutrition deaths. 12 Of the estimated 921 000 (95% confidence interval 812 000-1 117 000) pneumonia deaths that occurred in children under 5 years of age in 2015, most occurred among young children living in TB endemic areas. 13 In these settings, TB is likely to be a substantial cause and
Children suffer a huge burden of disease in tuberculosis (TB) endemic countries. This disease burden was largely invisible when TB control programmes focused exclusively on adults with sputum smearpositive disease. High-level advocacy and better data have improved visibility, but the establishment of functional paediatric TB programmes remains challenging. The key issues that limit children's access to TB preventive therapy and treatment in endemic areas are briefly discussed. Barriers to preventive therapy include (1) the perceived inability to rule out active disease, (2) fear of creating drug resistance, TB is an important preventable cause of under-5 mortality, since children respond well to treatment if they are able to access care.
Barriers to treatment access
High-level advocacy is essential, but it needs to be sustained and amplified at national and local levels to support effective implementation strategies. Few TB endemic countries have adequate strategies or resources allocated to implement TB prevention and care programmes for children. The WHO Roadmap for Childhood TB also emphasizes the need for better linkage and integration with maternal and child health (MCH) initiatives. 17 In some countries, significant progress has been made with child TB action plans jointly developed by national TB programmes (NTPs), local paediatric societies, and MCH programmes. 18 In response to the Roadmap's call for better linkages, the United Nations Children's Fund (UNICEF) recently organized a consultation meeting on childhood TB integration in New York, exploring how best to strengthen community and primary health systems.
19 Table 1 summarizes key barriers that continue to limit children's access to TB preventive therapy and treatment. 20 
Preventive therapy
The most effective means to prevent TB infection (and subsequent disease) in children is to improve epidemic control. 21 However, in settings with ongoing TB transmission, efforts to prevent TB disease are necessary to reduce TB-related morbidity and mortality in the most vulnerable. 22 The WHO and the International Union Against TB and Lung Disease (The Union) advise preventive therapy for all immunocompromised children and those less than 5 years of age (irrespective of their immune status) following proven TB infection or close contact with an infectious TB case. 23 Although this is rarely implemented in TB endemic settings and massive policy-practice gaps remain, 24 the creation of a latent TB infection (LTBI) taskforce and publication of evidence-based LTBI guidelines in 2015 25 demonstrates the commitment of the WHO to improve the delivery of preventive therapy to young and vulnerable children.
2.1.1. Perceived inability to rule out active disease A major concern of health care workers in resource-limited settings is their perceived inability to rule out TB disease with certainty, given the impression that a tuberculin skin test (TST) or interferon-gamma release assay (IGRA) and chest radiograph are required for adequate screening. However, symptom-based screening offers a safe and feasible alternative, [26] [27] [28] and is recommended by the WHO for contact screening in resourcelimited settings. 23 Chest radiography has little value in completely asymptomatic children 27, 29 and should not act as a barrier to the provision of preventive therapy in high-risk contacts. Detailed diagnostic work-up should be reserved for the minority of contacts with persistent symptoms suggestive of TB.
23,27
Fear of creating drug resistance
The exclusion of TB disease is important, since inadvertent treatment of active disease with one or two drugs used in preventive therapy could select for drug resistance. Fear of selecting drug-resistant strains that will be transmitted within the community is the most frequently cited reason why health care workers and countries are reluctant to implement preventive therapy strategies. 20, 24 The risk of acquiring drug resistance is greatest in patients with high organism loads and generally low if international screening guidelines are adhered to. 30, 31 It is conceivable that the selective pressure imposed by populationwide preventive therapy will be substantial, even though no elevated risk of drug resistance has been observed among those receiving TB preventive therapy in small-scale studies of limited duration. 32 However, the use of preventive therapy in young children is associated with minimal risk, as they tend to develop paucibacillary disease and rarely transmit the infection. 33 Therefore fear of creating drug resistance within the community is irrelevant and should not compromise the provision of preventive therapy to young children.
Non-implementation of existing guidelines
Despite the sound scientific basis underlying current recommendations and the drafting of international and national recommendations, contact screening is rarely implemented in Table 1 Barriers identified and solutions proposed to improve TB preventive therapy and treatment access for children
Barriers identified
Solutions proposed TB endemic settings. 24 Although health care services are overburdened, TB contact screening can be implemented with minimal additional resourcing and the use of simplified processes. This has been demonstrated by studies in Indonesia and with progressive country-wide roll-out of household contact tracing in Vietnam. 18, 28 In reality, TB programme implementation is largely driven by effective monitoring and evaluation. The fact that the WHO now requires NTPs to report on the provision of preventive therapy to child TB contacts, will encourage NTPs to develop feasible strategies, set realistic goals, and monitor implementation progress.
Poor adherence with prolonged isoniazid preventive therapy
Poor adherence with prolonged isoniazid preventive therapy (IPT) is a concern, 34 but recent field trials have demonstrated that good adherence is possible under programmatic conditions. 35, 36 Feasibility and adherence would be greatly improved by shortcourse therapy options, such as 3 months of daily isoniazid and rifampicin or 12 weekly-doses of isoniazid and rifapentine. 37 The availability of a water dissolvable fixed-dose combination tablet that contains 50 mg isoniazid and 75 mg rifampicin offers excellent opportunities to revive preventive therapy programmes and improve adherence, 38 especially in settings with low rates of HIV co-infection where potential drug-drug interactions caused by rifampicin are not of concern. It is hoped that child-friendly isoniazid and rifapentine combination tablets will also be developed, since this will greatly simplify preventive therapy administration and supervision.
Treatment of disease
An optimally formulated child-friendly dissolvable fixed-dose combination tablet, developed by the TB Alliance, has recently been made available via the Global Drug Facility. 38 Countries should ensure that this is purchased and made available to all children who require TB treatment. However, perceived diagnostic difficulties, the non-availability of chest radiography, and poor laboratory infrastructure remain major barriers to accurate diagnosis and treatment in resource-limited settings. Although better diagnostics and improved access to high quality digital chest radiographs are urgently needed, most cases of childhood TB can be diagnosed accurately using a systematic approach -even in resource-limited settings. 39, 40 Since most young children with symptoms suggestive of TB will present to MCH services and not to the NTP, it is essential that MCH programmes in TB endemic areas include training on childhood TB, integrate TB into integrated management of childhood illness (IMCI) approaches, and embrace TB service delivery. The WHO recently launched an online childhood TB training toolkit, which is freely available to all health care workers. 41 
Drug-resistant disease
There is currently no formal guidance on the use of preventive therapy following drug-resistant TB exposure. Although more data are required, the available evidence suggests benefit to young children with documented infection following MDR-TB exposure. 42 Unlike adults, treatment outcomes for children with drugresistant TB are excellent, but few are able to access proper diagnosis and care. 43 Treatment for drug-resistant TB is usually restricted to cases with bacteriologically confirmed disease, which excludes most young children. Although it is important to expand access to Xpert MTB/RIF and culture for bacteriological confirmation of drug-resistant TB, it is important for programmes to endorse the treatment of young children according to the drug susceptibility profile (DST) of their most likely source case, in the absence of bacteriological confirmation from their own specimens. 44 The Union recently developed an online course on the management of childhood MDR-TB, which offers useful guidance to clinicians and health care workers caring for children with TB. 45 Children tolerate most second-line drugs well, but close monitoring is important to limit drug-related adverse effects. 44 Given the limited information we have on the optimal administration of second-line drugs to children, it is essential to ensure that all new TB drugs have a paediatric development plan. 46 
Conclusions
In conclusion, there is a need for better collaboration between paediatricians, NTPs, and MCH initiatives in TB endemic countries to improve the detection and management of children with TB. Priority actions previously identified and emphasized by the Child TB Roadmap include the following: 47 (1) Empower children, their families, and communities to advocate for improved access to TB prevention, diagnosis, and care. (2) Step up programmatic efforts to identify children and adolescents most at risk of TB and prevent, diagnose, and treat them with the best diagnostic tools and medicines available. 
